COVID-19 vaccination in patients with epilepsy: First experiences in a German tertiary epilepsy center.
COVID-19 vaccination in patients with epilepsy: First experiences in a German tertiary epilepsy center.
复制标题
DOI：
10.1016/j.yebeh.2021.108160
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Baumgartner T
中科院分区：
文献类型：
--
作者：
von Wrede R;Pukropski J;Moskau-Hartmann S;Surges R;Baumgartner T
鉴于癫痫患者（PWE）对COVID-19疫苗接种信息的高需求，我们评估了PWE接种COVID-19疫苗后的症状和癫痫控制情况。所有在我们中心接受治疗的成年患者都被要求报告他们的疫苗接种情况，如果接种了疫苗，则报告他们在第一次接种COVID-19疫苗后的不良反应和癫痫发作控制经历。54名PWE已经接受了第一次针对COVID-19的疫苗接种（27名女性，20%无癫痫发作，96<%服用抗癫痫药物），并被纳入研究。三分之二的人对疫苗的耐受性一般很好或很好。33%的人报告了一般接种疫苗的不良反应。据报道，最常见的不良反应依次为头痛、疲劳、发烧和颤抖。在癫痫相关不良反应方面，1例患者报告首次接种COVID-19疫苗后1天癫痫发作频率增加，1例报告出现新的癫痫发作类型。没有患者报告癫痫持续状态或既往不良反应加重。我们的数据表明，PWE患者对COVID-19疫苗的耐受性良好，支持对PWE进行疫苗接种的建议。
Due to the high demand for information regarding COVID-19 vaccination in people with epilepsy (PWE), we assessed the symptoms and seizure control of PWE following their COVID-19 vaccination. All adult patients who were treated at our center were asked to report on their vaccination status and, if vaccinated, about their experiences following their first COVID-19 vaccination with regard to adverse effects and seizure control. Fifty-four PWE have already received their first vaccination against COVID-19 (27 female, 20% seizure free, 96<% on antiseizure medication) and were included in the study. Two-thirds tolerated the vaccines generally either very well or well. Thirty-three percent reported general vaccination adverse effects. The most frequently reported general adverse effects were, in descending order, headache, fatigue and fever, and shivering. With regard to epilepsy-related adverse effects, one patient reported increased seizure frequency one day after the first COVID-19 vaccination was administered, and one reported the occurrence of a new seizure type. None of the patients reported a status epilepticus or aggravation of preexisting adverse effects. Our data suggest that vaccination against COVID-19 appears to be well tolerated in PWE, supporting the recommendation of vaccination to PWE.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
11.2
作者：
VICKREY, BG;HAYS, RD;BROOK, RH
通讯作者：
BROOK, RH
影响因子：
2.6
作者：
von Wrede, Randi;Moskau-Hartmann, Susanna;Helmstaedter, Christoph
通讯作者：
Helmstaedter, Christoph
影响因子：
2.4
作者：
Top KA;Brna P;Ye L;Smith B
通讯作者：
Smith B
影响因子：
5.6
作者：
Tro-Baumann, Blanca;von Spiczak, Sarah;Kluger, Gerhard
通讯作者：
Kluger, Gerhard